Multimodality treatment with surgery for locally advanced non-small-cell lung cancer with n2 disease: a review...

Area of Science:

• Oncology
• Thoracic Surgery
• Pulmonology

Background:

• Stage III non-small-cell lung cancer (NSCLC) presents diverse clinical and pathological characteristics, complicating treatment planning.
• The optimal therapeutic strategy for resectable stage III NSCLC, particularly concerning the role of surgery, remains a subject of ongoing debate.

Purpose of the Study:

• To review and synthesize findings from retrospective and prospective studies on multimodality treatment including surgery for stage III NSCLC.
• To specifically evaluate the significance of surgical intervention in patients with mediastinal lymph node metastasis.

Main Methods:

• Systematic review of existing retrospective and prospective research.
• Analysis of treatment outcomes for stage III NSCLC patients undergoing multimodality therapy with surgical resection.

Main Results:

• Evidence synthesis indicates variability in outcomes depending on specific T and N staging within stage III NSCLC.
• Studies suggest potential benefits of multimodality treatment, but the definitive role of surgery, especially in cases with lymph node involvement, requires further clarification.

Conclusions:

• The heterogeneity of stage III NSCLC necessitates individualized treatment approaches.
• Further research is crucial to establish definitive guidelines for surgical and multimodality treatment in resectable stage III NSCLC, particularly for patients with mediastinal lymph node metastasis.